annual accounts payable:
$19.13M+$3.44M(+21.88%)Summary
- As of today (July 1, 2025), PCRX annual accounts payable is $19.13 million, with the most recent change of +$3.44 million (+21.88%) on December 31, 2024.
- During the last 3 years, PCRX annual accounts payable has risen by +$8.59 million (+81.48%).
- PCRX annual accounts payable is now at all-time high.
Performance
PCRX Accounts payable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly accounts payable:
$23.17M+$4.04M(+21.11%)Summary
- As of today (July 1, 2025), PCRX quarterly accounts payable is $23.17 million, with the most recent change of +$4.04 million (+21.11%) on March 31, 2025.
- Over the past year, PCRX quarterly accounts payable has increased by +$14.19 million (+157.98%).
- PCRX quarterly accounts payable is now -4.27% below its all-time high of $24.21 million, reached on June 30, 2023.
Performance
PCRX quarterly accounts payable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Accounts payable Formula
Accounts Payable = Beginning Accounts Payable + Purchases on Credit − Payments to Suppliers
PCRX Accounts payable Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +21.9% | +158.0% |
| 3 y3 years | +81.5% | +56.1% |
| 5 y5 years | +49.5% | +46.2% |
PCRX Accounts payable Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +81.5% | -4.3% | +158.0% |
| 5 y | 5-year | at high | +83.4% | -4.3% | +193.5% |
| alltime | all time | at high | +644.8% | -4.3% | +5166.4% |
PCRX Accounts payable History
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2025 | - | $23.17M(+21.1%) |
| Dec 2024 | $19.13M(+21.9%) | $19.13M(-1.2%) |
| Sep 2024 | - | $19.37M(+3.4%) |
| Jun 2024 | - | $18.73M(+108.5%) |
| Mar 2024 | - | $8.98M(-42.8%) |
| Dec 2023 | $15.70M(+3.1%) | $15.70M(-4.9%) |
| Sep 2023 | - | $16.51M(-31.8%) |
| Jun 2023 | - | $24.21M(+40.2%) |
| Mar 2023 | - | $17.26M(+13.4%) |
| Dec 2022 | $15.22M(+44.4%) | $15.22M(+17.7%) |
| Sep 2022 | - | $12.93M(-7.5%) |
| Jun 2022 | - | $13.98M(-5.8%) |
| Mar 2022 | - | $14.84M(+40.8%) |
| Dec 2021 | $10.54M(+1.1%) | $10.54M(+33.5%) |
| Sep 2021 | - | $7.89M(-35.2%) |
| Jun 2021 | - | $12.18M(+33.7%) |
| Mar 2021 | - | $9.11M(-12.7%) |
| Dec 2020 | $10.43M(-18.5%) | $10.43M(-19.8%) |
| Sep 2020 | - | $13.01M(+42.0%) |
| Jun 2020 | - | $9.16M(-42.2%) |
| Mar 2020 | - | $15.85M(+23.8%) |
| Dec 2019 | $12.80M(-10.9%) | $12.80M(-20.3%) |
| Sep 2019 | - | $16.06M(+20.4%) |
| Jun 2019 | - | $13.35M(-0.2%) |
| Mar 2019 | - | $13.37M(-7.0%) |
| Dec 2018 | $14.37M(-2.0%) | $14.37M(+4.2%) |
| Sep 2018 | - | $13.79M(-3.3%) |
| Jun 2018 | - | $14.26M(-4.4%) |
| Mar 2018 | - | $14.91M(+1.7%) |
| Dec 2017 | $14.66M | $14.66M(+19.4%) |
| Sep 2017 | - | $12.28M(+18.1%) |
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2017 | - | $10.39M(+10.9%) |
| Mar 2017 | - | $9.37M(+24.8%) |
| Dec 2016 | $7.51M(-14.1%) | $7.51M(+3.1%) |
| Sep 2016 | - | $7.29M(+57.9%) |
| Jun 2016 | - | $4.61M(-56.0%) |
| Mar 2016 | - | $10.48M(+20.0%) |
| Dec 2015 | $8.74M(+29.3%) | $8.74M(+3.2%) |
| Sep 2015 | - | $8.47M(-36.3%) |
| Jun 2015 | - | $13.30M(+139.0%) |
| Mar 2015 | - | $5.57M(-17.7%) |
| Dec 2014 | $6.76M(+120.2%) | $6.76M(-12.8%) |
| Sep 2014 | - | $7.75M(+146.3%) |
| Jun 2014 | - | $3.15M(+20.7%) |
| Mar 2014 | - | $2.60M(-15.1%) |
| Dec 2013 | $3.07M(+19.5%) | $3.07M(+96.9%) |
| Sep 2013 | - | $1.56M(-8.9%) |
| Jun 2013 | - | $1.71M(+71.0%) |
| Mar 2013 | - | $1.00M(-61.0%) |
| Dec 2012 | $2.57M(-25.3%) | $2.57M(-46.4%) |
| Sep 2012 | - | $4.79M(+988.4%) |
| Jun 2012 | - | $440.00K(-80.9%) |
| Mar 2012 | - | $2.30M(-33.1%) |
| Dec 2011 | $3.44M(-43.0%) | $3.44M(-20.2%) |
| Sep 2011 | - | $4.31M(-14.6%) |
| Jun 2011 | - | $5.05M(-17.1%) |
| Mar 2011 | - | $6.10M(+1.0%) |
| Dec 2010 | $6.04M(-13.7%) | $6.04M(-13.9%) |
| Sep 2010 | - | $7.01M(+7.6%) |
| Jun 2010 | - | $6.52M(-6.7%) |
| Dec 2009 | $6.99M(-40.7%) | $6.99M |
| Dec 2008 | $11.79M | - |
FAQ
- What is Pacira BioSciences annual accounts payable?
- What is the all time high annual accounts payable for Pacira BioSciences?
- What is Pacira BioSciences annual accounts payable year-on-year change?
- What is Pacira BioSciences quarterly accounts payable?
- What is the all time high quarterly accounts payable for Pacira BioSciences?
- What is Pacira BioSciences quarterly accounts payable year-on-year change?
What is Pacira BioSciences annual accounts payable?
The current annual accounts payable of PCRX is $19.13M
What is the all time high annual accounts payable for Pacira BioSciences?
Pacira BioSciences all-time high annual accounts payable is $19.13M
What is Pacira BioSciences annual accounts payable year-on-year change?
Over the past year, PCRX annual accounts payable has changed by +$3.44M (+21.88%)
What is Pacira BioSciences quarterly accounts payable?
The current quarterly accounts payable of PCRX is $23.17M
What is the all time high quarterly accounts payable for Pacira BioSciences?
Pacira BioSciences all-time high quarterly accounts payable is $24.21M
What is Pacira BioSciences quarterly accounts payable year-on-year change?
Over the past year, PCRX quarterly accounts payable has changed by +$14.19M (+157.98%)